文献速递淋巴瘤造血干细胞移植与细胞治疗

自体与异基因造血干细胞移植治疗弥漫大B细胞淋巴瘤型Richter综合征

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
PubMed 文献 · Blood Adv · 2021-01-01

该注册研究评估现代靶向治疗时代自体移植(n=53)与异基因移植(n=118)治疗DLBCL-RS的结局。自体移植3年复发率37%、PFS 48%、OS 57%;异基因移植分别为30%、43%、52%。异基因移植中移植时缓解深度与结局相关,而细胞遗传学异常和既往新药治疗未影响结局。

要点

  • 自体移植后3年复发率37%、PFS 48%、OS 57%。
  • 异基因移植后3年复发率30%、PFS 43%、OS 52%。
  • 异基因移植中移植时缓解深度与PFS/OS显著相关(P<.0001)。

核心结论

  • 在靶向治疗时代,HCT可使治疗敏感的DLBCL-RS患者获得持久缓解,包括高危特征患者。

研究设计与样本

  • 国际血液与移植研究中心注册研究,评估现代治疗时代DLBCL-RS患者自体HCT(n=53)和异基因HCT(n=118)后的结局。

主要发现

  • 自体HCT组移植时完全缓解比例高于异基因HCT组(66% vs 34%)。
  • 异基因HCT组17p缺失比例(33% vs 7%)和既往接受新药比例(39% vs 10%)高于自体HCT组。
  • 自体HCT组3年复发率37%、PFS 48%、OS 57%。
  • 异基因HCT组3年复发率30%、PFS 43%、OS 52%。
  • 异基因HCT组移植时缓解深度与3年PFS/OS相关:完全缓解66%/77%,部分缓解43%/57%,耐药5%/15%(P<.0001)。

临床怎么用

  • 对治疗敏感的DLBCL-RS患者可考虑HCT以获持久缓解。
  • 异基因HCT前应尽可能加深缓解,因移植时缓解深度与结局强相关。

局限性

  • 注册研究设计可能存在选择偏倚。
  • 样本量有限(自体n=53,异基因n=118)。
  • 未评估靶向治疗时代前与后的直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Richter syndrome (RS) represents a transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), which is associated with a dismal prognosis. Patients with DLBCL-RS have poor outcomes with DLBCL-directed therapy; thus, consolidation with hematopoietic cell transplantation (HCT) has been used, with durable remissions observed. Studies reporting HCT outcomes in patients with DLBCL-RS have been small, have not evaluated the prognostic impact of cytogenetic risk factors, and were conducted prior to the era of novel targeted therapy of CLL/SLL. We performed a Center for International Blood and Transplant Research registry study evaluating outcomes after autologous HCT (auto-HCT; n = 53) and allogeneic HCT (allo-HCT; n = 118) in patients with DLBCL-RS treated in the modern era. More auto-HCT recipients were in complete response (CR) at HCT relative to allo-HCT recipients (66% vs 34%), whereas a higher proportion of allo-HCT recipients had 17p deletion (33% vs 7%) and had previously received novel agents (39% vs 10%). In the auto-HCT cohort, the 3-year relapse incidence, progression-free survival (PFS), and overall survival (OS) were 37%, 48%, and 57%, respectively. Among allo-HCT recipients, the 3-year relapse incidence, PFS, and OS were 30%, 43%, and 52%, respectively. In the allo-HCT cohort, deeper response at HCT was associated with outcomes (3-year PFS/OS, 66%/77% CR vs 43%/57% partial response vs 5%/15% resistant; P < .0001 for both), whereas cytogenetic abnormalities and prior novel therapy did not impact outcomes. In our study, HCT resulted in durable remissions in therapy-sensitive patients with DLBCL-RS treated in the era of targeted CLL/SLL therapy, including patients with high-risk features.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Herrera AF, Ahn KW, Litovich C, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021. PMID: 34496026. doi:10.1182/bloodadvances.2021004865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。